Structural characterization of form I of anhydrous rifampicin | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Feeds:: Posts; Comments

« New cocrystals of ezetimibe with L-proline and imidazole

Cocrystals of telmisartan: characterization, structure elucidation, in vivo and toxicity studies »

Structural characterization of form I of anhydrous rifampicin

August 29, 2014 by larryhbern

Another informative post of what goes into pharmaceutical analysis.

Larry H Bernstein, MD, FCAP

Posted in Uncategorized | Leave a Comment

Leave a Reply Cancel reply

Follow Blog via Email

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,656 other subscribers

Email Address
Recent Posts
- NCCN Shares Latest Expert Recommendations for Prostate Cancer in Spanish and Portuguese September 14, 2021
- Standard Operating Procedures for Updating the Map of LPBI India August 24, 2021
- New avenues for research in membrane biology reveals the mobility of protein at work August 23, 2021
- Can the Public Benefit Company Structure Save US Healthcare? August 20, 2021
- Patients with type 2 diabetes may soon receive artificial pancreas and a smartphone app assistance August 13, 2021
- CNS immune interface August 9, 2021
- 3D printing: Improvising the Next-generation Batteries August 8, 2021
- Novartis uses a ‘dimmer switch’ medication to fine-tune gene therapy candidates August 7, 2021
- LPBI Group announces 5th Academic INTERNSHIP as a Verifiable Certificate in Financial Modeling & Econometrics as One Semester or as One Year Program open to Undergraduate and MBA students August 7, 2021
- Science Policy Forum: Should we trust healthcare explanations from AI predictive systems? July 31, 2021
Archives
Archives
Categories
Categories
Meta

%d bloggers like this: